Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Cattolica

3 clinical trials in Cattolica, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cattolica at a glance
3
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

3 trials in Cattolica

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Lung adenocarcinoma

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Carboplatin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Hormone receptor positive HER2 negative breast cancer

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Cattolica

What the registry says about research in the country

01 Cattolica
Breast Cancer Therapeutics
In Cattolica, researchers are evaluating a new oral therapy for node‑positive, estrogen receptor‑positive, HER2‑negative early breast cancer that carries a high risk of recurrence. The trial compares this agent with standard endocrine treatment to determine its impact on disease‑free survival. Assessment of Elacestrant in various combination regimens Comparison to conventional endocrine therapy Measurement of invasive breast cancer‑free survival as primary endpoint Inclusion of both women and men with high‑risk disease All three studies in the city are actively recruiting, with a team of 53 investigators committed to advancing breast cancer care.
Advanced Non‑Small Cell Lung Cancer Immunotherapy
A separate study in Cattolica focuses on elderly patients with advanced NSCLC, exploring whether initiating treatment with durvalumab improves survival compared to starting with standard chemotherapy. Safety, especially early mortality, is a key concern. First‑line immunotherapy followed by chemotherapy at progression Evaluation of 12‑month overall survival outcomes Safety monitoring of death rates within the first four months Targeting patients with PDL1 ≥25% or unknown expression The trial remains open for enrollment, reflecting the city’s active role in oncology research.
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.